Forum Archive Index - April 2002

["Nick Kearney" <nickk@quicksilver.net.nz>]

Derek

Good stuff here.  I am biased though.  I hold PTD.  I agree that there is
good opportunity for buying here.  May need to close over $2.94 for
confirmation though.  Keep it coming Derek.

Nk


----- Original Message -----
From: "Derek" <dkw@paradise.net.nz>
To: <sharechat@sharechat.co.nz>
Sent: Wednesday, April 24, 2002 8:50 PM
Subject: [sharechat] PTD


> Quote from SharesWeekly, beginning of March 2002, note the last sentence.
>
> "Last month Peptech finally received the news everyone was waiting for.
The
> US Patent
> Office granted Peptech a "notice of allowance" for its TNF antibody patent
> in the US.
> This means companies with TNF antibody drugs on the market, such as
> Centocor, and
> companies with TNF antibody drugs in development, such as Abbot
> Laboratories, will
> be required to pay Peptech royalties for the next 11 years. What is also
> good news for
> Peptech is that it has already settled with these two groups.
>
> The patent is a divisional patent and is not as broad as that granted in
> Europe. This
> means companies such as Immunex, which has developed TNF drugs that are
not
> complete antibodies, are not covered under this divisional patent.
However,
> Peptech is
> looking to submit additional divisional patent applications in the US to
> broaden cover
> to all TNF drugs, although the possibility of this being granted is
remote."
>
> Actually I think that PTD could be good buying soon, The Abbot drug looks
like
> be a real winner and if PTD does miss out on patents that cover Immunex's
> 'Enbrel'  etc
> it may not be the end of the world.
>
> My only misgiving is related to the immune suppression that these anti-TNF
> drugs have,
> I can't help wonder if their long term use will see an increase in cancer
> in users.
> clinical trials are all very well, but they may not run long enough to
pick
> up such
> an effect. To date however there are no statistics to suggest a problem,
see
> http://www.cnn.com/2001/HEALTH/conditions/08/17/arthritis.drug.safety/
>
> But there is this -
> "The FDA did, however, tell Immunex to study Enbrel's long-term effects,
>   in case it affects the immune system enough to increase patients' risk
of
> infections or possibly even cancer."
> (from http://acmi.canoe.ca/HealthNews/981103_arthritis.html )
>
> Time will tell,
>
> Regards,
> Derek
>
> disc. Not currently holding PTD
>
>
> --------------------------------------------------------------------------
--
> To remove yourself from this list, please use the form at
> http://www.sharechat.co.nz/chat/forum/
>
>


----------------------------------------------------------------------------
To remove yourself from this list, please use the form at
http://www.sharechat.co.nz/chat/forum/